# Yusuke Okuma

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yusuke-okuma/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,316 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 31 |
| i10-index | 107 |
| Last Known Institution | National Cancer Center Hospital East |
| OpenAlex ID | https://openalex.org/A5002845200 |
| ORCID iD | 0000-0001-5743-0149 |
| Works | 389 |

## Researcher papers

- [The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer](https://scholariq.org/papers/the-gut-microbiome-associates-with-immune-checkpoint-inhibition-outcomes-in/)
- [Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial](https://scholariq.org/papers/lenvatinib-in-patients-with-advanced-or-metastatic-thymic-carcinoma-remora-a/)
- [C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan](https://scholariq.org/papers/c-cat-the-national-datacenter-for-cancer-genomic-medicine-in-japan/)
- [High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer](https://scholariq.org/papers/high-plasma-levels-of-soluble-programmed-cell-death-ligand-1-are-prognostic-for/)
- [The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV](https://scholariq.org/papers/the-japanese-lung-cancer-society-guideline-for-non-small-cell-lung-cancer-stage/)
- [Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer](https://scholariq.org/papers/soluble-programmed-cell-death-ligand-1-as-a-novel-biomarker-for-nivolumab/)
- [Impact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer](https://scholariq.org/papers/impact-of-prior-antibiotic-use-on-the-efficacy-of-nivolumab-for-non-small-cell/)
- [Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression](https://scholariq.org/papers/efficacy-of-anti-pd-1-antibodies-in-nsclc-patients-with-an-egfr-mutation-and/)
- [Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy](https://scholariq.org/papers/key-components-of-chemotherapy-for-thymic-malignancies-a-systematic-review-and/)
- [First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations](https://scholariq.org/papers/first-line-osimertinib-for-previously-untreated-patients-with-nsclc-and-uncommon/)
- [EP.06B.14 Differential Expression in Potential Therapeutic Target Protein by Treatment in Small Cell Lung Cancer with and without Transformation](https://scholariq.org/papers/ep-06b-14-differential-expression-in-potential-therapeutic-target-protein-by/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Myasthenia Gravis and Thymoma](https://scholariq.org/topics/myasthenia-gravis-and-thymoma/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [National Cancer Center Hospital East](https://scholariq.org/institutions/national-cancer-center-hospital-east/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.